FDA Letter API

Metro Vapors, LLC

Letter data

Company
Metro Vapors, LLC
Recipient
Brandon Parrish | Metro Vapors, LLC | Metro Vapors, LLC | 403 S. Highway 78 | Wylie | , | TX | 75098-3964 | United States | info@metrovaporshop.com
Issue date
2018-11-14
Posted date
Not available
FDA office
Center for Tobacco Products
Subject
Not available
Product
Not available
CMS ID
562955
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Metro Vapors, LLC MARCS-CMS 562955 — November 14, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: UPS and Electronic Mail Recipient: Recipient Name Brandon Parrish Metro Vapors, LLC Metro Vapors, LLC 403 S. Highway 78 Wylie , TX 75098-3964 United States info@metrovaporshop.com Issuing Office: Center for Tobacco Products 10903 New Hampshire Avenue Silver Spring , MD 20993 United States Dear Brandon Parrish: On September 12, 2018, the United States Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Candy King Sour Worms e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your Candy King Sour Worms e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children. On October 1, 2018, you sent FDA a response to the Warning Letter, and we held a teleconference on November 8, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violation identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violation identified in the Warning Letter. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future. Should you have any questions or concerns, please contact me at (301 ) 796-9235 or by email at elenita. ibarrapratt@fda . hhs.qov. Sincerely, /S/ Ele Ibarra-Pratt Division Director Office of Compliance and Enforcement Center for Tobacco Products cc: Azim Chowdhury Keller and Heckman LLP 1001 G Street NW, Suite 500 West Washington, DC 20001 chowdhury@khlaw.com Brandon Parrish 5736 Highway 78 Suite A Sachse, TX 75048 Domains by Proxy, LLC metrovaporshop.com@domainsbyproxy.com GoDaddy.com, LLC abuse@godaddy.com BigCommerce Inc. abuse@bigcommerce.com Content current as of: 03/04/2019